Transcripts
Vertex Pharmaceuticals Incorporated (VRTX) Presents at BofA Securities 2023 Health Care Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) BofA Securities 2023 Health Care Conference May 9, 2023 12:20 PM ET
Company Participants
Charlie Wagner – EVP and CFO
David Altshuler – CSO and EVP, Global Research
Conference Call Participants
Geoff Meacham – Bank of America
Geoff Meacham
Welcome to the first morning of the BofA Healthcare Conference. I’m Geoff Meacham. I’m the senior biopharma analyst here and we’re thrilled to have Vertex Pharmaceuticals in the big room, hopefully no protesting this year. But on behalf of Vertex, we have Charlie Wagner, Executive VP and CFO; and David Altshuler, who is CSO and EVP, Global Research. Guys, welcome.
David Altshuler
Thank you.
Charlie Wagner
Yes, Geoff, thank you. Thanks for hosting.
Geoff Meacham
So Charlie, do you want to just post the quarter, just give us a little bit of a high level and then we’ll get into some questions.
Charlie Wagner
Yes. Yes, listen, the 2023 is off to a fantastic start for us. We continue to reach more and more CF patients with our medicines. We commented in the first quarter. We continue to execute on launches in countries where we received reimbursements late last year. We’ve added some incremental new reimbursements, and we continue to move into younger age groups, notably with the approval of TRIKAFTA in the 2 to 5 age group. So with that strong and steady and consistent performance. We’ve reaffirmed our revenue guidance for the year of $9.55 billion to $9.7 billion and the year is off to a great start.
It’s also a year that will have a number of milestones that will mark the advancement and progress of our pipeline. We commented that we recently completed our rolling submission for the BLA for exa-cel and beta-thal and sickle cell in the U.S. We have commented that we will have updates data on the type 1 diabetes program around midyear. We expect to complete our VANZA triple Phase III trial later this year, and we expect to complete our Phase III trial in acute pain later this year or early next year. So a steady cadence of data and information throughout the year, and we’re really proud of being able to show progress in the pipeline. Again, everything is off to a great start, and we’re happy to be here.
Question-and-Answer Session
Q – Geoff Meacham
Perfect. Well, let’s go — let’s start off with that. So the Vanzacaftor. When you think about the — what’s left with TRIKAFTA, how should we imagine this product commercially. And then clinically, what are some of the opportunities that you see to differentiate aside from the dosing?
Charlie Wagner
Do you want to talk clinically?
David Altshuler
Sure. So obviously, TRIKAFTA is a great medicine. We’ve seen not only the short-term benefits that we saw in the additional clinical trials but also the long-term benefits have now been defined, including, as we described last year, 75-plus percent reductions in mortality in hospitalizations and transplant with TRIKAFTA. So beating that is certainly going to be very difficult. But we’ve got a lot of confidence in the Vanzacaftor triple because one thing we’ve learned in the field has learned is that the best predictor of long-term outcomes is the level of CFTR function. We know that because the disease is caused by CFTR mutations. We know that because people have mutations that have different levels of function have different outcomes. But if you have a carrier who has one normal copy, you have no disease whatsoever.
And so our goal is to get everyone to carrier levels. And then finally, we know from our clinical trials that when we’ve analyzed the data and divided it and said, people who have more normal levels of CFTR function closer to carrier versus ones who are not, the ones with higher levels of CFTR function do better. So all of those scientific and medical things tell us that getting patients to higher level of CFTR function towards carrier is the goal. We know with TRIKAFTA, only a minority of people are at carrier levels. And finally, we know that the Vanza triple can drive higher levels of CFTR function. We know that in vitro in our HB assays that have predicted outcome time after time and also based on the clinical data in Phase II. So from all of that data, we believe and we see the field believing that getting patients to carrier levels should be the goal and if the outcome of the Phase III trial is that we can achieve what we predict, which is higher levels of CFTR function and the profile supportive of those greater benefits, then patients will have a good new option that may really do well for them.
Charlie Wagner
Maybe just commercially, too, we think, Vanza, can be a key part of the company’s growth story over the next several years. We commented — we recently updated our estimate of patients in North America, Europe and Australia to 88,000, roughly 5,000 of whom are waiting for an mRNA therapy, but of the remaining 83,000, we had about 20,000 left to reach with the medicine as of the beginning of the year, highly confident in our ability to reach them for the reasons I outlined about the first quarter performance is executing on launches, new reimbursements moving to younger age groups. But with Vanza, there’s the opportunity for patients to, we believe, switch to an even superior medicine. There’s also within that subset of patients, we’re not treating today with CFTR modulators, there are 6,000 or so who have discontinued from previous Vertex medicines who would have the opportunity to come back on medicine. And so that’s a driver of growth. And as I mentioned, the mRNA therapy. So whether it’s 2023 or beyond, we see a meaningful opportunity to continue to grow in CF.
Geoff Meacham
Right. Let’s talk about the mRNA platform. So the X mutations or premature stop mutation patients are the ones in CF that haven’t really been able to benefit. And you guys are in a Phase I collaboration with Moderna. Maybe just give us the challenges historically in this patient population. And then the LNP and the innovations that you guys have developed to try to tackle this population.
David Altshuler
Yes. It’s really very compelling when you talk to these patients because it’s unusual. There’s patients with CF and 90% of them or so are now having their lives really improved by CFTR modulators, but there’s the last 5,000 or so who can’t respond because they don’t make any protein, and they’re watching their friends and their — and their loved ones from the clinics and the people they know, get better and they’re not. So we’re very motivated to try and help them. The challenge we believe is that the bronchial-epithelial cells, the cells you have to get to, to help patients are designed to keep particles and viruses and things like that out of them.
They’re the lining of the lung. And you think every time you Inhale, there’s some particles and virus as you might inhale. And those cells are the guards. They’re the defense that keeps them out. And so maybe it’s not surprising that no one for 30 years has been able to get into those cells. When we started with Moderna some 7 years ago, we took all of the LNPs people had published and tried and none of them could get into those cells. And those cells remember the ones that have predicted reproducibly the success of our CFTR modulators.
So we set out to find a new LNP that could do that, and it was hard. It actually took us 5 years. And for a long time, we weren’t even sure we’d ever get there. But we did crack the problem a couple of years ago. We were able to get high levels of CFTR function with this LNP mRNA we invented. And also then we went to small and large animals and safety studies that had a really attractive profile. So we think this is really the first time anyone has ever been able to go into the clinic with something that can treat the cells that matter, which is the bronchial-epithelial cells, you’ll even see that some of the others who have tried have published things saying we were able to do it in this seller that cell, but not the human bronchial-epithelial cell and we are able to do that at high level. So that’s why we’re optimistic. The study, as you said, is open. We cleared the IND late last year. The study is open, and it’s going to be a single ascending dose because it’s a new modality, a new agent. And then after that, assuming everything looks good, which we’re confident it will, we’ll go to multiple ascending dose and fingers crossed, it will help patients.
Geoff Meacham
Got you. Well, let’s switch gears because you guys have a lot to talk about with respect to the pipeline. So exa-cel, which is sickle cell and beta-thal submission filed, I guess we’ll have to see whether the filing is accepted coming up. But give us a perspective on what investments you’ve made commercially? And how do you see the initial wave and potentially of this in the U.S. playing out with regard to the sickle cell opportunity.
Charlie Wagner
Sure. I mean I think the headline is, while we are, of course, waiting for our PDUFA date, we are not waiting to be fully prepared commercially, and we will be fully prepared commercially this year. We’ve mentioned — we see the opportunity roughly 160,000 patients worldwide across the two diseases. 20% or so of whom we think would be eligible candidates with existing therapy and existing conditioning regimens, so 32,000 of that 25 in sickle cell, 7 in beta thalassemia and the sickle cell patients largely concentrated in the U.S. And so in terms of commercial efforts, we’ve identified I think in the U.S., it’s basically 25 states is where you would find 80% of the sickle cell patients. In Europe, it’s about five countries. We think that with 50 authorized treatment centers in the U.S. and 25 in Europe, we can get to the vast majority of patients who would be appropriate early on.
As a result, we are building out our commercial capabilities around — we’re engaged with all of those centers already working through details around contracting, logistics, et cetera. Aside from that, we’re also engaging with the federal government, state governments and private payers to ensure that reimbursement will be available for patients as soon as possible after approval. This is a disease area that has been underserved for a very long time, and we see strong tailwinds at all levels for payers wanting to step up and ensure that these patients have access to the best therapy. So we’re super busy. We’re meeting regularly on commercial readiness. It takes up quite a bit of our time. And the investment is reflected in our OpEx guidance for the year and will be reflected in our run rate as we exit ’23.
Geoff Meacham
Got you. Okay. That’s helpful. Bigger picture, though, when you look at the therapy itself, gene editing, broadly gene therapy, cell therapy, there have been some bumps along the road with respect to a number of companies, right, regulatory uncertainty give us your confidence level and the data set that you have and a seamless sort of path to potentially approve.
David Altshuler
Yes. We feel extremely confident in the package we have. And the reasons for that are multiple: First, the clinical profile that we’ve seen and we presented last year at EHA is remarkable with, as you know, 77 patients treated at that time, 33 patients with sickle cell, all of whom had two or more pain crises a year. They were, at that time, no pain crisis in the follow-up since the 33 patients were treated, the transfusion-dependent thalassemia patients, all of whom had multiple transfusions a year to stay alive. Of the 44, 42 were transfusion free since treatment and the other 2 had like a 80% or more reduction in transfusion frequency. So it’s a remarkable profile. And I think that it’s also a large data set compared to what some other companies have done.
And then the other thing that companies have run into perhaps that we are sure, very confident will not happen for us is they either didn’t engage with the regulators along the way, and we did from the very beginning. And as you’ll know, last year, you remember we were saying, well, we can’t tell you exactly when we’ll file because we’ve got to work out the last things with the FDA, and we successfully reached alignment with them. And so we’re confident the package we’ve put into the U.S., the U.K. and EU are consistent with what they’re looking for in terms of the package.
And then finally, the last thing is manufacturing. I think the thing that really challenged many of the smaller companies that were sort of moving very rapidly from academia to a couple of patient proof of concept was they didn’t develop their manufacturing, their analytical development, all of their methods for commercialization, they develop it to get to a so-called value inflection. And then when they got to that place and others took over the program, they had to start again.
In 2015, when we did the deal with CRISPR during that period, the first few years, I ran it directly with my colleagues and Sam and other people at CRISPR, and like we would sit there right at the beginning, and I give CRISPR for a lot of credit. It was like, what are we going to do today that will allow us to use a pivotal process that we can commercialize. And I think that experience of together thinking in 2015, ’16 and ’17 has meant we haven’t had to change our process. And so you see other companies having to do that. And we — so I think that — those are all the reasons I feel like it goes to planning. It goes to preparation. And I think the plan from the beginning to get to commercialization not just to get to a value inflection.
Geoff Meacham
You guys have made some investments with respect to improving the conditioning regimen. Talk a little bit about that and how important that is strategically to the kind of the long-term value of exa-cel.
David Altshuler
Yes. So the initial patients we’re focused on, as Charlie was saying, is there’s 32,000 patients, 25,000 in the U.S. who have severe sickle cell or beta-thal. And those patients just to give you a sense of how actively how much they’re suffering and how actively they engage with the healthcare system. It’s been estimated that their lifetime burden is $4 million to $6 million for each of those patients. So they’re very frequent users of the healthcare system and suffering a lot. And with regard to those patients, we think dystrophy busulfan conditioning, which is the exa-cel approach for launch is appropriate that has a favorable benefit risk. But clearly, it is a substantial commitment on the part of the patient and it would obviously be desirable to not have to deal with chemotherapy, the busulfan. And that would also open up the opportunity, presumably for the rest of the 150-or-so thousand patients who might not choose busulfan. We have an internal research effort bolstered by business development where we get assets, technologies capabilities. And we are moving forward very aggressively to bring one or possibly multiple shots on goal, if you will, to have better conditioning. We don’t think that will — that’s not today, and we don’t think the absence of it will stand in the way for those 32,000 people who are suffering so much today, but to get to the larger opportunity is going to be important, and we’re forging ahead.
Geoff Meacham
Right. You mentioned the economic cost. Are there investments that you think you could make going forward that could further delineate the cost benefit of this program? Or is it going to be obvious once you get the label for the drug and it starts to roll out commercially as you’re talking to payers?
Charlie Wagner
Yes. I mean, the label is important. But as with all of our medicines, we are shooting for a transformative benefit in people with really, really serious diseases. And — so part of that, of course, is the label, but we invest a ton of time in working with key opinion leaders, working with payers, working with governments, doing our own health economic research and really driving understanding, not only of the benefit to the patient, but the ancillary benefits to the healthcare system. And so those investments are, in fact, happening today. It’s — we take a kind of a multichannel approach and really surround the disease with as much information as we can.
Geoff Meacham
Is there a compare contrast with OUS markets, for this, when you think about the opportunity, I know that’s probably not the first wave. But typically, though, in Europe, for example, you still have infusion centers, you still have patients. You mentioned there’s less patients that you’ve identified globally that are in Europe, for example, but it’s still part of the launch, though.
Charlie Wagner
Absolutely. As I mentioned, there are four or five countries in Europe where we see 80% of the opportunity that will absolutely be part of our kind of first wave launch. Sickle cell is very much — is more common in the U.S. It’s about 100,000 people. So like 3x as many people as CF with similar levels of severity in terms of shortened life and time in the hospital, all that. In Europe, there’s more beta thalassemia. And again, just to give you a sense, the severe form beta thalassemia, you don’t make any red cells. And if you don’t have transfusions, you die because you don’t have red cells. And so that just gives you a sense of what these people are living with. And so a medicine that could mean instead of a lifetime of getting the blood transfusions, then getting iron overload which is called hemochromatosis because your body doesn’t have any way to excrete iron.
So if you get blood transfusions all the time, you end up with another disease called hemochromatosis because you have iron overload. So onetime treatment that could eliminate all that. I think its value is pretty clear even to people all around the world.
Geoff Meacham
And we got a lot of questions on compare and contrast with one of your competitors, Lovo-cel. Maybe just give us the puts and takes of the dynamic there.
David Altshuler
Yes. I mean, the way we think about it is that, first of all, obviously, the clinical profile matters a lot, and we think that our benefit risk and safety tolerability is very, very strong. But the other is, if you think about what you’d like to do if you’re doing a genetic therapy or a gene editing therapy is, you’d like to make whatever precise change you desire in order to help the patient, and you don’t want to do anything else because anything else you do might lead to undesired consequences. And the thing about CRISPR is — and the reason it sort of took the world by storm is that it’s a method that if you do it right and you pick the right guide that’s very unique in the genome, it’s highly effective, but it’s also highly precise and specific.
And so with exa-cel, we see high rates of editing at the exact place in the genome defined by naturally occurring human genetic mutations is where you want to edit and no other editing anywhere else has ever been detected. And so I contrast that just with other approaches that lead to random insertional mutagenesis in every cell. And so that is a mutagenic process. And it’s just — I think patients and doctors will — they’ll have their choice potentially. And I think that a precise approach that doesn’t have any of those undesired insertions probably would be preferable. And we see that in some of the research done. But in the end, Vertex always — if there’s multiple options for patients and they’re good for patients, then patients have choices, we just think that they’ll likely make the choice to go with our profile.
Geoff Meacham
And you guys have been working with CRISPR for a while. So give us a perspective on how much of a strategic priority is it for Vertex to be one of the leaders in the gene editing, cell therapy space what other diseases look attractive to you at this point?
David Altshuler
Well, the key thing is the Vertex strategy is really disease based, more than platform-based. We start with unmet need. We actually look at where there’s gaps in the treatment algorithm patients are suffering, then we look at where we think that we can make a transformative benefit to both the target has to be human validated. So trying to avoid all those — all that attrition that happens when you don’t go after a human validated target, but also find the right modality. And then, of course, it has to be a specialty market, so it fits our business model. And when you do all that, you end up finding opportunities like sickle cell or type 1 diabetes that are really very large opportunities, if we can, not just with exa-cel or VX-880, but through serial innovation, as we did in CF, going from KALYDECO or OKRAMBI, SYMDEKO, TRIKAFTA over a decade. If we can get from the first patients treated to large numbers, those opportunities are really quite large for Vertex in the world. that’s more our approach than saying we want to be a gene editing company, and then we have to look for other opportunities.
Having said that, obviously, if you have a small molecule expertise, there are projects you can do no one else can. And if we can, and I think we will commercialize the first CRISPR therapy with exa-cel and commercialize hopefully down the road, the first fully differentiated stem cell therapy with type 1, that will certainly give us a foundation. And there are other diseases, you can imagine, some of which we’re working on already. You know that we have a DMD program using gene editing. We bought the company, Exonics, and there are other diseases you can think of for cell therapy. And so we’ll look for those opportunities. But we think the most important thing for Vertex and for our patients and probably for our shareholders is that we really succeed in type 1 and sickle cell and get to those large numbers of patients and build the foundation on which other opportunities could eventually be added.
Geoff Meacham
So let’s switch gears to type 1 diabetes. So you guys have had some data on a few patients. I wanted to ask you like what should we expect in terms of more patients, longer follow-up. What’s sort of the next, say, 12 months look like for that program?
David Altshuler
Yes. As I mentioned in the opening remarks, we will release more data on the program around the middle of this year. I think in terms of — it’s important to understand the structure of the trial. Obviously, it’s a program that we’re very excited about the new modality. So the trial is conducted in three parts: Part A, Part B, Part C. Part A was two patients at half dose to establish safety. And those patients had to be staggered apart. So dose one patient, wait, dose one patient wait. Once that was completed, we were able to move into Part B. Part B is five patients at full dose, but also staggered. So that explains the time since we last reported data on the program, you dose, you wait, you dose, you wait.
Our intention, and we will expect to move into Part C this year, but in terms of data to expect around the middle of the year, we will publish data on the patients in Part A and Part B. So it will be more patients than we’ve previously reported on and longer duration for a number of those patients.
Geoff Meacham
Got you. And from the technology perspective, it’s a bit of a unique approach in type 1 diabetes. What have been some of the challenges? And looking forward, are there sort of edits to this platform technology that you guys could make to further address those?
David Altshuler
No, it’s a great question. So let me start saying my background, clinically, I’m a physician, and I’m a diabetes doctor, and Doug Melton and I started talking about he did all the work. But we started talking about this idea 30 years ago when his son Sam was diagnosed with type 1 diabetes. I was an MD-PhD student at the time. And it’s been clear for decades that if you — that — it’s been clear for a century that this disease is a pure absence of the insulin-producing islets of the pancreas. There’s no other problem. And it’s been clear since 19 — for the last 20 years that you can cure the disease by transplanting islets, cadaveric islets and cure the disease. And you have to compare that to what people do otherwise, which is they have to measure their blood sugar constantly throughout the day.
They have to either inject themselves four times a day or they have to take a continuous infusion of insulin. If they ever stop insulin within three days, you’ll be in an emergency room, within two days after that, you’ll be an ICU and the life expectancy without in the insulin treatment is weeks. So — and then finally, the average American patient, despite all of the good advances we’ve had in insulin care, is actually not anywhere near the control that is the goal, which is hemoglobin A of 7%. The average in America is much higher than that. So all of this speaks to a huge unmet need in type 1 diabetes.
The key challenge was making the cells. And the reason I say that is the transplant of cadaveric islets or pancreas does work, but it’s only done very rarely. And you might ask, well, if it works, why isn’t it done? And the reason is there’s no supply. The reason is because when someone passes away, the first — the pancreas is in the middle of the body, and it’s a bag of digestive enzymes and it starts to auto digest. And it’s very difficult to get islets out of the pancreas, usually you need like multiple donors, and it’s just not possible. So the key advance was Doug Melton spending 25 years after his son and daughter were diagnosed with type 1, figuring how to make stem cells into fully differentiated islets that in every way we can measure are indistinguishable from the islets inside of our own bodies. That’s like measuring them with every sequence — the RNA of every cell and see the profile of RNAs, they look just like islets taken from the body. You can put them in a dish expose them to different stimuli. They make insulin. You can put them in animals. They will cure the disease. And now you’ve seen the first patient we treated with the half safety dose off insulin with normal glucose control based on initial reports. So it’s really a remarkable story.
Now the key thing other than just treating more patients, as Charlie described, and obviously, it’s going to take a little while with the stagger to get more experience protecting those cells from the immune system. But there are three shots on goal because they’re an [allo] product. It’s off the shelf. It’s not like our sickle cell program, which is each patient for themselves, and these patients have auto immunity. That’s what caused their disease in the first place. So the first approach we’re taking VX-880 is with immunosuppression that is a clinical standard when people have the islet transplants that use this, and we’re using it, too. So the number of variables is the fewest. We have the device, which protects the cells, that’s VX-264 and that trial is open — we have the open regulatory, the IND and CTA in the U.S. and Canada. And then we are also working on editing the cells, as you said, hypo-immune to try and figure out ways to make them less visible to the immune system.
And I think the key thing is the cells are actually the transformative advance there are many multiple ways to protect in the immune system, and we will test each one, learn in the clinic. If one of them turns out to have, as I think it will, favorable profile. Some may hopefully get approved and be something for patients, but we’ll also keep iterating as Vertex always does.
Our goal, very clearly, is to get to the 2.5 million people in the U.S. and Europe and then eventually more around the world with this disease. And just to close on this point as a diabetologist, I’ve never met a patient with diabetes type 1 who wants to inject themselves with insulin all the time who wants to have to go through every day, always think about their diet, measuring their blood sugar and knows that if they take too much insulin, they will lose consciousness. And if they take too little, they run the risk of all these complications.
So I think that like if we can get there, and I believe we will, it’s like — it’s transformative.
Geoff Meacham
Well, in the last few minutes, I’ll talk about the pain program. So you guys are in Phase III development on acute pain and Phase II neuropathic pain. I guess, Charlie, from a commercial perspective, what work have you guys done and what work is left to do on helping to set the stage for having to state and local governments like a non-opioid alternative. How valuable do you think that is recognized by payers.
Charlie Wagner
David can add on the target product profile. But our experience is that — and our view is that a medicine that is even equivalent to but perhaps superior to an opioid in terms of efficacy without the addictive potential and without all of the side effects is transformative, and there’s incredible demand for that. We’ve looked at the market opportunity today in acute pain. Right now, patients have a choice between NSAIDs and opioids and the market is roughly a $4 billion market at 90% generic pricing. Our view is that a medicine with that transformative profile with branded pricing has an opportunity to make the market much larger.
And just think about from a patient perspective, if you’re going in and having knee surgery or some sort of other procedure that costs thousands of dollars, the actual cost of your pain treatment is tiny relative to the overall cost of the procedure. So we think there’s an incredible potential there. As you point out, we’re talking, of course, with hospital systems, but we’re also talking with state governments. We’re talking with the federal government. States — all 50 states have restrictions on opioid prescriptions. Nearly 20 of them have actually requirement for physicians to look for non-opioid alternatives before they prescribe — those are restrictions, if you will. But importantly, at the federal government level, the No Pain Act was passed recently, which stands for non-opioids prevent addiction in our nation. Again it’s a hard one to remember. And what that creates is a separate payment for non-op — separate Medicare payment for non-opioids in the outpatient setting. Not to say that, that takes care of all of the reimbursement needs, but we think it’s a really clear indication of the top-down kind of policy support for non-opioids. And we expect there to be additional developments in that front going forward. So we’re sort of attacking it at all levels.
David, of course, and the kind of the science folks and the clinicians within our company are doing their best to drive the program forward. But on the commercial side, we’re readying as well. And again, that investment is ramping up throughout the year.
David Altshuler
Yes. Just three quick points. One is — the trials are going well. We’re on track to complete the Phase III program and the Phase II neuropathic pain program end of the year, early next. Second, we do as Vertex always does have follow-ons, and they could be potentially superior both with NAV18, we’ve also taken what we learned in NAV18. We think we’ve cracked in the labs, NAV17. So this is not, again, the last medicine Vertex will ever make in pain. This is the start of what I think will be a true revolution in pain treatment. And then the third thing I’d just say is my word — of 35 seconds. My wife had shoulder surgery a couple of months ago. And like everybody, I don’t know how many people in the audience have had surgery recently. She was sent home with two days of opioids. She’s still in pain 2.5 months later. Tylenol and Advil don’t really do it. And if you realize not just the cost — I think what I hear people talk about, they talk about what are the pain medicine cost? You have to think about, as Charlie said, the hospitalization, the surgery, the months of recovery, the PT all the things that go into this and the amount of money that we’re talking about, whatever it might be for improved pain control is trivial compared to the suffering and also the impact on the healthcare system, how many times do people go back to the doctor because I’m still in pain and that might not happen. So I think people are thinking sort of narrowly rather than at an enterprise level about what this could mean to the health care system and most importantly, patients.
Geoff Meacham
Right. Well, thank you, guys. We’re out of time. So I appreciate the time.
Charlie Wagner
Yes. Thank you.
David Altshuler
Thanks for having us.